< Back to News

CHNA ETF Video Series: Zai Lab

Nov. 16, 2018

Today we are unveiling the first installment in a video series we have captured highlighting China BioPharma ETF (Nasdaq: CHNA) companies and the important work they are doing. Rather than just tell you about the companies, we wanted to show you them. These videos highlight the people, facilities, and science, and allow you to hear straight from CEOs about what their work is focused on. Our team traveled to Shanghai and Hong Kong this fall on your behalf because we wanted to give you this visual sense of what it is like to visit these impressive companies. We captured footage with four CHNA ETF companies and also made a visit to the Hong Kong Stock Exchange. We hope you enjoy these behind the scenes looks at what the biopharmaceutical industry is like in China. Watch for the videos to hit your inbox in the coming months.

The first video released today is with Zai Lab (Nasdaq: ZLAB). The company is based in Shanghai and was founded in 2014 by a Chinese entrepreneur named Samantha Du. Dr. Du began her career with Pfizer in the United States where she worked on the scientific side of Pfizer’s global metabolic licensing program. Since returning home to China, she was a co-founder and Chief Scientific Officer of Hutchison China MediTech, and managing director of healthcare investments for Sequoia Capital China. In this video, you will hear Dr. Du talk about her passion for improving lives of patients through drug development and why she thinks China is on the rise in life sciences. Also featured are Zai Lab CFO Billy Cho and the Chief Medical Officer for Oncology Yongjiang Hei.

As Dr. Hei says in the video, Zai Lab has been a pioneer in its business model. The company has a good understanding of Chinese patients and how to develop drugs in China and has started off in-licensing drugs from biotech companies in the United States that might be well suited for the region. Developing these drugs locally requires this China specific knowhow. In the meantime, they are also focused on developing the internal capacity to discover new things of their own. Given how drug discovery takes a long time, this model of in-licensing might given Zai Lab the near term revenue needed to establish its business until that longer term strategy of internal innovation gets into high gear. Below is a look at Zai Lab’s current development pipeline. You will notice a heavy emphasis on cancer research, but also autoimmune and infectious disease.



One of Zai Lab’s lead programs revolves around the cancer drug Niraparib, which was in-licensed from Tesaro in the United States. This is a PARP inhibitor, which works by blocking a cancer cell’s ability to repair breaks in DNA and replicate. Other popular drugs in this class include AstraZenca’s Lynparza and Clovis Oncology’s Rubraca. Zai Lab is developing Niraparib in China for cancers such as ovarian, lung, and others. In fact, Niraparib was recently approved for patients with relapsed ovarian cancer in Hong Kong and the company has already started commercializing it there. This is their first opportunity at earning revenue from the sale of a new medicine. They also have multiple phase 3 studies ongoing in mainland China in some of those other indications and hope to commercialize it there one day soon as well.

Another program we find interesting is Zai Lab’s partnership with Five Prime on FPA144 in gastric cancer. The incidence of gastric cancer in China is significantly greater than the United States, with 680,000 new cases annually. Given the importance of this market for the drug, Zai Lab was able to secure a worldwide royalty on it when they signed the deal with Five Prime. The two companies announced on October 1st that the first patient has been dosed in a phase 3 global registration trial for which Zai Lab is conducting the China cohort. FPA144 is an isoform-selective FGF receptor 2b (FGFR2b) and patients are being selected who over express FGFR2b so this is considered a targeted therapy. Gastric cancer is a big unmet need that is very difficult to treat and we wish both companies luck on this program.

Lastly, we would like to highlight a collaboration that Zai Lab recently struck with Novocure. Novocure has a platform technology called Tumor Treating Fields. This uses electric fields tuned to different frequencies to disrupt cell division. It is currently already FDA approved 
in the United States and by regulators in Europe for the treatment of a type of brain cancer called glioblasta multiforme (GBM) and is also under development for other types of cancers as well. The marketing name for the GBM treatment is Optune. GBM is a challenging cancer to treat and Optune has proven itself to make a difference for some patients. Zai Lab will be the exclusive developer and distributor of Optune in Greater China. There is currently only one approved therapy in the country for GBM, a drug called Temozolomide, and new therapies are needed because this is another very difficult to treat cancer.

The China BioPharma ETF would like to thank Zai Lab for its participation in our video series and we wish everyone there the best of luck as they aim to make a difference for patients. We also hope that you, our investors and other readers, find these videos to be valuable educational tools. Our strong belief is that there is something special brewing in China’s life sciences sector today, but it is hard to articulate the totality of it in words alone. Since not everyone has the opportunity to travel to China to see it in person, our aim is to bring China’s biopharmaceutical sector you through these videos. We hope they do justice to telling the story of how compelling the people, places, and science are in China today. Thank you for your interest in the China BioPharma ETF.

See all holdings of the China BioPharma ETF.

Opinions expressed are those of the author or Funds and are subject to change, are not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Fund holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell any security. AstraZenca, Clovis Oncology, FivePrime, Novocure, and Pfizer are not a holding of the Fund or affiliated with the Fund.

  • Loncar Funds
  • P.O Box 15072
  • Lenexa, KS 66285
  • +1 800-617-0004
  • Contact Us

CNCR Prospectus CHNA Prospectus

A basis point is a common unit of measure for interest rates and other percentages in finance. One basis point is equal to 1/100th of 1%, or 0.01% (0.0001).

The Loncar Cancer Immunotherapy Index is an index of 30 securities that have a strategic focus on the area of cancer immunotherapy, or harnessing the immune system to fight cancer. Quotes for the index can be found under the symbol “LCINDX” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

The Loncar China BioPharma Index is an index of 50 securities that have a strategic focus on advancing China’s biopharma industry. Quotes for the index can be found under the symbol “LCHINA” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

Holdings are subject to change.

The Hong Kong Stock Exchange (HKEX) is the primary stock exchange in the Hong Kong Special Administrative Region of China. Nasdaq is one of the primary stock exchanges in the United States.

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus, which may be obtained at Read the prospectus carefully before investing.

Investing involves risk. Principal loss is possible. The fund may trade at a premium or discount to NAV. CNCR will invest in immunotherapy companies which are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The costs associated with developing new drugs can be significant, and the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals with be obtained and maintained. The Fund may invest in foreign securities, which involve political, economic, currency risk, greater volatility, and differences in accounting methods. The Fund is non-diversified meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. The Fund invests in smaller companies, which may have more limited liquidity and greater volatility compared to larger companies. The Fund is not actively managed and may be affected by a general decline in market segments related to the index. The fund invests in securities included in, or representative of securities included in, the index, regardless of their investment merits. The performance of the fund may diverge from that of the Index and may experience tracking error to a greater extent than a fund that seeks to replicate an index. Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

RISK FOR THE CHNA ETF: The biopharmaceutical industry in China is strictly regulated and changes in such regulations, including banning or limiting certain products, may have a material adverse effect on the operations, revenues, and profitability of Biopharma Companies. The laws and regulations applicable to the process of administrative approval of medicine and its production in China require entities producing biopharma products to comply strictly with certain standards and specifications promulgated by the government. Changes in currency exchange rates and the relative value of non-U.S. currencies will affect the value of the investment. Currency exchange rates can be very volatile and can change quickly and unpredictably. Investments in non-U.S. securities involve certain risks that may not be present with investments in U.S. securities. For example, investments in non-U.S. securities may be subject to risk of loss due to foreign currency fluctuations or to political or economic instability. Investments in non-U.S. securities also may be subject to withholding or other taxes and may be subject to additional trading, settlement, custodial, and operational risks. These and other factors can make investments in the Fund more volatile and potentially less liquid than other types of investments. To the extent the Fund invests a significant portion of its assets in the securities of companies of a single country or region, such as China, it is more likely to be impacted by events or conditions affecting that country or region. The Fund is a recently organized, non-diversified management investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision. The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund. The Fund is not actively managed and the Fund's sub-adviser would not sell shares of an equity security due to current or projected underperformance of a security, industry or sector, unless that security is removed from the Index or the selling of shares of that security is otherwise required upon a reconstitution of the Index in accordance with the Index methodology. To the extent the Fund invests more heavily in particular sectors of the economy, its performance will be especially sensitive to developments that significantly affect those sectors."

Diversification may not protect against market risk.

Exchange Traded Concepts, LLC serves as the investment advisor, and Vident Investment Advisory, LLC serves as a sub advisor to the fund. The Funds are distributed by Quasar Distributors, LLC, which is not affiliated with Exchange Traded Concepts, LLC or any of its affiliates.